Clinical Trials · NCT07871409
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Amgen
- Enrollment
- 230
- Start date
- Oct 2026
- Locations
- 1 site, United States
- Primary endpoint
- Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home Administration